Avanza Fonder AB Invests $4.56 Million in Becton, Dickinson and Company $BDX

Key Points

• Avanza Fonder AB has acquired 26,492 shares of Becton, Dickinson and Company, valued at approximately $4.56 million, marking a new position for the firm in the medical instruments supplier.
• Several large investors, including Northcape Wealth Management and Alpha Omega Wealth Management, have also adjusted their stakes in Becton, Dickinson and Company, with overall institutional ownership at 86.97%.
• The company reported $3.68 EPS for the latest quarter, exceeding analyst estimates, and has set a FY 2025 guidance at 14.300-14.450 EPS.

Avanza Fonder AB purchased a new stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 26,492 shares of the medical instruments supplier's stock, valued at approximately $4,563,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Northcape Wealth Management LLC boosted its holdings in Becton, Dickinson and Company by 0.5% during the 1st quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier's stock valued at $2,248,000 after acquiring an additional 51 shares during the period. Alpha Omega Wealth Management LLC boosted its position in shares of Becton, Dickinson and Company by 5.7% during the 1st quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier's stock worth $225,000 after purchasing an additional 53 shares in the last quarter. Brady Family Wealth LLC raised its stake in shares of Becton, Dickinson and Company by 1.2% during the 1st quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier's stock worth $989,000 after buying an additional 53 shares during the last quarter. Diversified Trust Co lifted its holdings in Becton, Dickinson and Company by 4.7% in the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier's stock valued at $272,000 after purchasing an additional 53 shares in the last quarter. Finally, REAP Financial Group LLC increased its stake in shares of Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 55 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Insider Activity

In related news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Claire Fraser sold 917 shares of the company's stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the transaction, the director directly owned 22,226 shares of the company's stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,965 shares of company stock worth $551,536. Corporate insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Stock Down 0.2%

Shares of NYSE BDX traded down $0.30 during midday trading on Monday, hitting $186.74. The company's stock had a trading volume of 1,227,724 shares, compared to its average volume of 1,592,393. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The business's fifty day simple moving average is $187.84 and its two-hundred day simple moving average is $189.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The firm has a market capitalization of $53.53 billion, a price-to-earnings ratio of 33.59, a price-to-earnings-growth ratio of 1.51 and a beta of 0.27.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. The business's revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter last year, the company earned $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio is 74.82%.

Analyst Ratings Changes

BDX has been the topic of several research analyst reports. Argus raised their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Barclays lowered their target price on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research note on Tuesday, June 3rd. Piper Sandler reiterated a "neutral" rating and set a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Morgan Stanley upped their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Four analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of "Hold" and an average price target of $213.30.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.